Results 1 to 10 of about 4,546 (176)

Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients [PDF]

Thoracic Cancer
Background Second‐generation anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and brigatinib, are widely used in patients with ALK‐positive non‐small cell lung cancer (NSCLC) who develop resistance or progress on crizotinib. However, real‐
Min Jee Kim, Hyun Seok Kwak, Eun Nim Koh, Cheol‐Kyu Park, Young‐Chul Kim, In‐Jae Oh, Seung Joon Kim, Jun Hyeok Lim, Jeong‐Seon Ryu, Chang Min Choi   +9 more
doaj   +2 more sources

Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China [PDF]

Oncology and Therapy
Introduction Brigatinib and alectinib are anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (ALK-TKIs) approved in China in 2022 and 2018, respectively, for the treatment of patients with ALK-positive, advanced non‑small‑cell lung cancer (NSCLC)
Qingqing Chai, Congling Gu, Luis Hernandez, Yan-Jun Zhang   +3 more
doaj   +2 more sources

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma [PDF]

Frontiers in Oncology
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as brigatinib, are targeted therapies for metastatic non-small cell lung cancer (mNSCLC).
Khyati Somayaji Dasika, Megan Melody, Jyoti D. Patel   +2 more
doaj   +2 more sources

Unilateral cystic and bullous lung changes in a patient treated with brigatinib: a case report [PDF]

Korean Journal of Clinical Oncology
Approximately 3% to 5% of individuals with oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene develop non-small cell lung cancer (NSCLC).
Anuradha Nalika Godallage, Pradeesh Sivapalan, Vladmira Horvat, Simon Trøster, Shailesh Kolekar   +4 more
doaj   +2 more sources

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report [PDF]

Current Oncology
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used in treating patients with EGFR-mutated non-small-cell lung cancers (NSCLCs), especially in cases with secondary resistance mutations ...
Daphnée Demers, Marie Florescu
doaj   +2 more sources

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells [PDF]

Frontiers in Pharmacology
BackgroundBrigatinib is approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Qi Yang, Dan Zhao, Linjie Ju, Peng Cao, Jifu Wei, Zhixian Liu   +5 more
doaj   +2 more sources

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements [PDF]

Therapeutic Advances in Medical Oncology
Background and objectives: This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ...
Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah Young Shin, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Jeong Uk Lim, Chang Dong Yeo   +9 more
doaj   +2 more sources

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report [PDF]

Frontiers in Oncology
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by ...
Yang Zhang, Ke-jie Li, Can Wang, Chang-lin Zou, Meng Su   +4 more
doaj   +2 more sources

Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study [PDF]

Drugs - Real World Outcomes
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor was licensed for the treatment of ALK-positive metastatic non-small cell lung cancer in 2016.
Claudio Martin, Gabriela Ileana Malcervelli, Gastón Lucas Martinengo, Patricio Levit, Patricio Servienti, Elisa Malaver, Laura Brion, Vanesa Patronella, Andrea Zumárraga, Jose Zarba   +9 more
doaj   +2 more sources

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial [PDF]

, 2021
Introduction: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS ...
Ahn M. -J., Califano R., Camidge D. R., Delmonte A., Felip E., Garcia Campelo M. R., Gettinger S. N., Griesinger F., Han J. -Y., Hochmair M. J., Kim D. -W., Kim H. R., Lee K. H., Lin H. M., Liu Y., Niu H., Popat S., Spira A. I., Tiseo M., Vranceanu F., Yang J. C. H., Zhang P.   +21 more
core   +4 more sources